AbCellera is a biotechnology company that works with pharmaceutical industry partners to accelerate the discovery of monoclonal antibody therapeutics (mAbs). mAbs are molecules that are naturally produced by the immune system to fight off infections and diseases.
These molecules have the ability to precisely target diseased cells or pathogens, making them highly effective treatments with low side effects for cancer, autoimmune disorders and infections.
AbCellera uses microfluidic technologies to rapidly measure the properties of mAbs produced by single immune cells, thereby increasing the efficiency of the mAb discovery process while harnessing the natural power of the immune response.
